368 related articles for article (PubMed ID: 28373467)
1. Efficacy of Single-dose First-generation 5-HT
Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
[TBL] [Abstract][Full Text] [Related]
2. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
3. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K
BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy.
Kawazoe H; Motoki Y; Takechi Y; Shishino Y; Ido K; Suemaru K; Araki H
Methods Find Exp Clin Pharmacol; 2010 Sep; 32(7):499-505. PubMed ID: 21069101
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
[TBL] [Abstract][Full Text] [Related]
9. Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial.
Iihara H; Iwai M; Morita R; Fujita Y; Ohgino K; Ishihara T; Hirose C; Suzuki Y; Masubuchi K; Kawazoe H; Kawae D; Aihara K; Endo S; Fukunaga K; Yamazaki M; Tamura T; Kitamura Y; Fukui S; Endo J; Suzuki A
Lung Cancer; 2024 Jun; 192():107801. PubMed ID: 38678830
[TBL] [Abstract][Full Text] [Related]
10. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
12. Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Suzuki S; Karayama M; Inui N; Kuroishi S; Fujisawa T; Enomoto N; Nakamura Y; Yokomura K; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Hayakawa H; Suda T
Med Oncol; 2016 Jul; 33(7):65. PubMed ID: 27235141
[TBL] [Abstract][Full Text] [Related]
13. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
BMC Cancer; 2022 Mar; 22(1):310. PubMed ID: 35321690
[TBL] [Abstract][Full Text] [Related]
14. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis.
Hayashi T; Shimokawa M; Mizuki F; Matsuo K; Kawada K; Nakano T; Egawa T
Support Care Cancer; 2021 Sep; 29(9):5029-5035. PubMed ID: 33590260
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.
Sakai C; Shimokawa M; Iihara H; Fujita Y; Ikemura S; Hirose C; Kotake M; Funaguchi N; Gomyo T; Imai H; Hakamata J; Kaito D; Minato K; Arai T; Kawazoe H; Suzuki A; Ohno Y; Okura H
Oncologist; 2021 Jun; 26(6):e1066-e1072. PubMed ID: 33811782
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Iihara H; Shimokawa M; Hayasaki Y; Fujita Y; Abe M; Takenaka M; Yamamoto S; Arai T; Sakurai M; Mori M; Nakamura K; Kado N; Murase S; Shimaoka R; Suzuki A; Morishige KI
Gynecol Oncol; 2020 Mar; 156(3):629-635. PubMed ID: 31926638
[TBL] [Abstract][Full Text] [Related]
18. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
Hayashi T; Shimokawa M; Matsuo K; Iihara H; Kawada K; Nakano T; Egawa T
BMC Cancer; 2021 Jan; 21(1):74. PubMed ID: 33451299
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Hashizume J; Higuchi N; Sato K; Kodama Y; Matsunaga N; Sakamoto T; Yamaguchi K; Nakamura T; Kitahara T; Sasaki H
Biol Pharm Bull; 2016; 39(4):611-4. PubMed ID: 27040634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]